Edwards Lifesciences’ (EW) Buy Rating Reiterated at BTIG Research

Posted by Brenda Bartman on Sep 14th, 2026

BTIG Research reaffirmed their buy rating on shares of Edwards Lifesciences (NYSE:EW – Free Report) in a research note issued to investors on Friday,Benzinga reports. BTIG Research currently has a $110.00 price target on the medical research company’s stock.

Other research analysts have also recently issued reports about the company. Royal Bank Of Canada upped their price target on Edwards Lifesciences from $100.00 to $110.00 and gave the stock an “outperform” rating in a research note on Monday, July 13th. Citigroup boosted their price objective on Edwards Lifesciences from $101.00 to $110.00 and gave the company a “buy” rating in a report on Wednesday, July 8th. Piper Sandler restated an “overweight” rating and set a $101.00 target price (up from $100.00) on shares of Edwards Lifesciences in a report on Friday, July 24th. Evercore restated an “outperform” rating and set a $100.00 target price on shares of Edwards Lifesciences in a report on Monday, July 6th. Finally, TD Cowen reiterated a “buy” rating on shares of Edwards Lifesciences in a research note on Tuesday, July 21st. Seventeen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $100.27.

Read Our Latest Stock Analysis on EW

Edwards Lifesciences Stock Performance

NYSE EW opened at $84.54 on Friday. The stock has a market cap of $48.68 billion, a PE ratio of 48.59, a P/E/G ratio of 2.21 and a beta of 0.85. The company has a current ratio of 4.52, a quick ratio of 3.77 and a debt-to-equity ratio of 0.06. Edwards Lifesciences has a twelve month low of $72.30 and a twelve month high of $96.29. The stock has a fifty day simple moving average of $89.16 and a 200-day simple moving average of $85.81.

Edwards Lifesciences (NYSE:EW – Get Free Report) last announced its earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.04. The company had revenue of $1.74 billion during the quarter, compared to analyst estimates of $1.70 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. Edwards Lifesciences’s revenue was up 13.6% compared to the same quarter last year. During the same quarter last year, the firm posted $0.67 earnings per share. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Equities analysts anticipate that Edwards Lifesciences will post 3 earnings per share for the current year.

Insider Activity at Edwards Lifesciences

In related news, SVP Andrew M. Dahl sold 544 shares of the business’s stock in a transaction on Monday, August 31st. The stock was sold at an average price of $91.06, for a total transaction of $49,536.64. Following the completion of the transaction, the senior vice president directly owned 14,868 shares of the company’s stock, valued at $1,353,880.08. The trade was a 3.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Annette Brüls sold 2,644 shares of the company’s stock in a transaction dated Friday, August 28th. The stock was sold at an average price of $89.98, for a total value of $237,907.12. Following the sale, the vice president owned 17,984 shares in the company, valued at approximately $1,618,200.32. This trade represents a 12.82% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 5,664 shares of company stock worth $511,918. Company insiders own 0.31% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. California State Teachers Retirement System increased its position in shares of Edwards Lifesciences by 9,187.8% in the 2nd quarter. California State Teachers Retirement System now owns 80,962,062 shares of the medical research company’s stock valued at $7,323,828,000 after purchasing an additional 80,090,362 shares during the last quarter. BlackRock Inc. acquired a new position in shares of Edwards Lifesciences during the second quarter worth $5,318,092,000. Bank of New York Mellon Corp acquired a new position in shares of Edwards Lifesciences during the second quarter worth $1,274,082,000. Norges Bank acquired a new position in shares of Edwards Lifesciences during the fourth quarter worth $803,686,000. Finally, Bank of America Corp DE purchased a new position in Edwards Lifesciences in the second quarter valued at $605,397,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences News Roundup

Here are the key news stories impacting Edwards Lifesciences this week:

Positive Sentiment: CMS expands TAVR coverage: The Centers for Medicare and Medicaid Services will extend Medicare coverage to certain patients with severe aortic stenosis who do not yet have symptoms. The broader eligible patient population could increase demand for Edwards’ TAVR valves and procedures, a particularly important growth opportunity for the company. CMS expands TAVR Medicare coverage to asymptomatic patients
Positive Sentiment: Company welcomes the policy: Edwards said the national coverage determination should improve patient access to TAVR while reinforcing the role of multidisciplinary Heart Teams. The company also reaffirmed its 2026 financial guidance following the decision, suggesting no immediate deterioration in its outlook. Edwards Lifesciences Reaffirms 2026 Guidance Following Medicare TAVR Decision
Positive Sentiment: Analysts remain bullish: Citi initiated or reiterated a Buy view, while BTIG reaffirmed its Buy rating with a $110 price target. William Blair also maintained a Buy rating, citing the expanded TAVR coverage and inclusion of asymptomatic patients. These targets imply substantial potential upside from recent trading levels. Analyst Buy Rating on Edwards Lifesciences
Neutral Sentiment: Why the stock may still be under pressure: The reports identify no new company-specific negative catalyst. Investors may be waiting for evidence that the CMS change translates into procedure volumes and revenue, while Edwards’ relatively elevated valuation—about 49 times earnings—could make the shares sensitive to profit-taking or broader market weakness.

Edwards Lifesciences Company Profile

(Get Free Report)

Edwards Lifesciences Corporation (NYSE:EW) is a medical technology company focused on therapies for structural heart disease. Its products are designed to treat conditions affecting the heart valves and related cardiovascular structures, helping patients with diseases such as aortic stenosis, mitral regurgitation and tricuspid valve disorders.

The company’s portfolio includes transcatheter aortic valve replacement systems, including its SAPIEN platform, as well as transcatheter mitral and tricuspid therapies and surgical heart valve products.